First patient enrolled in Biodesix and Addario Lung Cancer Medical Institute Study aiming to predict patient survival using a blood-based biomarker.
Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time.
Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.
Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.
We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.
Presented by: Wallace Akerley, MD
Huntsman Cancer Institute
Chairman, Protocol Review & Monitoring Committee: Director, Lung Cancer Disease Center of Excellence, Medical Oncologist
Presenter: Robert Georgantas III, Ph.D.
SVP, Research and Translational Science
Recorded at IO 360 on February 25, 2021Watch Now